• EN
Search

Austria country overview — a summary of the national drug situation

 

 

Austria country overview
A summary of the national drug situation

Map of Austria

Our partner in Austria

The Austrian National Focal Point is located within the Gesundheit Österreich GmbH (GÖG), an NGO funded by the Ministry of Health. The GÖG has three business units, carrying out research, planning, monitoring and reporting activities (within the business unit ÖBIG), developing, implementing and evaluating a nationwide quality system for health care). Read more »

Gesundheit Österreich GmbH (GÖG)

Stubenring 6
A-1010 Wien
Tel. +43 15156160

Head of Focal Point: Ms Marion Weigl

Our partner in Austria

Gesundheit Österreich GmbH (GÖG)

Stubenring 6
A-1010 Wien
Tel. +43 15156160
Fax +43 15138472

Head of Focal Point: Ms Marion Weigl

The Austrian National Focal Point is located within the Gesundheit Österreich GmbH (GÖG), an NGO funded by the Ministry of Health. The GÖG has three business units, carrying out research, planning, monitoring and reporting activities (within the business unit ÖBIG), developing, implementing and evaluating a nationwide quality system for health care (within the business unit BIQG) as well as promoting and financing of health promotion activities (within the business unit FGÖ). The Austrian National Focal Point is located within the working area prevention in the business unit ÖBIG.

E-mail addresses have been inserted in a way discouraging spam. Please replace [a] by @ before actually using any of the e-mail addresses.

Drug use among the general population and young people

In 2004 and 2008 representative surveys on the prevalence and patterns of use of licit and illicit narcotic substances were carried out in Austria on behalf of the Federal Ministry of Health (BMG). In 2008 a total of 4 196 people over the age of 14 were interviewed about their experience of licit and illicit psychoactive substances. Cannabis was the most frequently used illicit substance reported by 15- to 64-year-olds, followed by amphetamines and ecstasy. Among 15- to 34-year-olds the lifetime prevalence of cannabis use was 19.2 %, followed by ecstasy at 3.3 % and amphetamines at 3.1 %. Only cannabis showed a last 12 month prevalence rate above 1 % (3.5 %) among all participants, while among 15- to 34-year-olds the prevalence for cannabis use was 6.6 %, followed by 1.2 % for cocaine and 1.0 % for amphetamine. Lifetime, last 12 month and last 30 days prevalence rates in the 2008 survey were lower for almost all drugs compared to the 2004 survey. However, it is likely that the main reasons for the change in prevalence relate to the methodology, rather than to an actual reduction.

In 2007 the European School Survey Project on Alcohol and Other Drugs (ESPAD) among 15- to 16-year-old pupils found an estimated lifetime prevalence of 17 % for cannabis use, followed by 14 % for volatile substances and other inhalants. Amphetamines and cocaine were less frequently used. Lifetime prevalence of cannabis use was higher among males (19 %) than females (15 %). Last year prevalence of cannabis use among all respondents was 14 %, and last month prevalence was 7 %. In 2003 lifetime prevalence of cannabis use was 21 %, and for volatile substances and other inhalants it was 14 %. According to data from the 2010 Health Behaviour in School-aged Children (HBSC) study, about 14 % of students aged 15–16 reported ever having used cannabis.

Look for Prevalence of drug use in the 'Statistical bulletin' for more information  

High-risk drug use

Up to 2012 the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) defined problem drug use as injecting drug use (IDU) or long duration/regular use of opiates, cocaine and/or amphetamines. However, in 2012 a new definition of ‘high-risk drug use’ was adopted. The new definition includes ‘problem drug use’, but is broader (mainly in its inclusion of high-risk use of more substances). Details are available here.

Estimates on the number of high-risk drug users in Austria are available for polydrug use, including opiates (thus corresponding to the definition of ‘high-risk opioid use’), and are calculated using the capture–recapture method based on two main sources: (i) police reports related to opioids; and (ii) the substitution treatment registry. They have been validated for some years using the special registry on drug-related deaths as a third source of data (3-sample CRC). The most recent estimate for 2013 indicated a prevalence of 4.99 high-risk opioid users per 1 000 inhabitants aged 15–64 (sensitivity interval: 4.86–5.12), or a total of 28 550 users (sensitivity interval: 27 790–29 311). Historically, an increase in the estimated number of high-risk opioid users was observed in the early to mid 2000s, and since 2009 a gradual decline has become apparent. In 2013, it is estimated that there are 11 000–15 000 opiate users who predominantly inject opiates, with sniffing being the other route of administration.

Based on data from the 2008 general population survey, it is estimated that about 0.2 % of 15- to 64-year-olds used cannabis daily or almost daily within the last 30 days.

Look for High risk drug-use in the Statistical bulletin for more information.  

Treatment demand

A nationwide documentation system on drug treatment centres, referred to as DOKLI, was initiated in 2005 and data have been available from 2006. In 2013 treatment demand data was gathered from 121 outpatient and 21 inpatient treatment centres in Austria. Another register, eSuchtmittel, records data on all patients receiving opioid substitution treatment (OST) in Austria. There is an overlap between DOKLI and eSuchtmittel, which may result in double counting of clients.

In 2013 a total of 3 631 clients entered treatment recorded in the DOKLI-system, of which 1 569 were new clients entering treatment for the first time. Most clients attended outpatient treatment centres. Opioids, mainly heroin, were reported as the primary drug by 52 % of all treatment clients with known primary substance. Cannabis was reported as a primary substance of abuse for 30 % of all treatment clients and cocaine was reported by 10 % of this group. Among new treatment clients, the majority (39.5 %) reported cannabis as their primary problem drug, followed by opioids at 23 % and cocaine at 9.2 %. Some 43 % of all treatment clients and 31 % of new treatment clients whose primary drug was opioid reported injecting it.

In terms of age distribution, the mean age for all treatment clients was 29 years in 2013. New treatment clients tended to be younger, with a mean age of 27. The gender distribution of all treatment clients was 76.9 % male and 23.1 % female, which is similar to that of new clients (79.2 % male and 20.8 % female).

Look for Treatment demand indicator in the Statistical bulletin for more information.  

Drug-related infectious diseases

The prevalence of infectious diseases among people who inject drugs (PWID) in Austria is estimated on the basis of samples from treatment facilities and low-threshold centres. For human immunodeficiency virus (HIV) and hepatitis C virus (HCV) information is also gathered from drug-related death autopsy reports, and from the Austrian HIV cohort study. In 2013 a total of 21 new cases of HIV infection among PWID were reported. The national prevalence rates of HIV among PWID ranged from 1.5–10.6 %.

The available data on the sub-national prevalence rates of hepatitis B virus (HBV) indicate prevalence rates of 2.7 % in 2013. HCV prevalence ranged from 31.3–59.9 % in 2012/13 (with higher rates in larger data sources). Compared to the previous years, the range for HCV rates from low-threshold centres and treatment facilities indicates a rising trend and stabilisation at a very high level after 2008. However, the data are based partly on both voluntary and mandatory tests, and are thus biased, which undermines any clear interpretation and representativeness.

Look for Drug-related infectious diseases in the Statistical bulletin for more information.  

Drug-induced deaths and mortality among drug users

The special registry at the Austrian National Focal Point collects and reports data on drug-induced deaths. Data extraction and reporting is in line with the EMCDDA definitions and recommendations.

In 2013 a total of 138 drug-induced deaths were reported. After a noticeable increase between 2003–06, the number of drug-induced deaths seems to show a slow decline. For 2013 some 119 deaths had known toxicological examinations. In 113 of these cases the presence of opioids was registered; however, similarly to previous years, a significant proportion of cases was attributed to polydrug use. With regard to gender, 113 of the registered cases were male. The average age at death was 32.1 years.

The drug-induced mortality rate among adults (15–64) was 24.2 deaths per million in 2012, above the European average of 17.2 deaths per million.

Look for Drug-related deaths in the Statistical bulletin for more information.  

Treatment responses

All nine Austrian provinces have drawn up drug strategies and nominated drug coordinators that are responsible for coordinating drug treatment at the regional level. A drug coordinator has been appointed to accredit and monitor treatment at the national level under the Ministry of Health. The Provincial Conference of Drug Coordinators performs inter-regional coordination of drug treatment policies. The provincial governments, the social insurance funds and the federal government primarily finance drug treatment.

Addiction treatment services are provided both by specialised centres and as part of general healthcare services (e.g. psychiatric hospitals, psychosocial services and office-based medical doctors). General healthcare services are largely involved in OST provision. Drug treatment services in Austria are very diverse. They provide a range of options and can be flexibly applied to respond to a client’s treatment and social needs. The treatment programmes are offered in modular form, providing both short-term and long-term options. Treatment is mostly provided on an outpatient basis, and the majority of the outpatient facilities are counselling centres. While counselling centres treat users of licit and illicit drugs, there are several specialised treatment and reintegration facilities available almost exclusively for illicit drug users. Outpatient psychosocial interventions cover a range of services, such as counselling, outreach work, psychotherapy, aftercare and reintegration programmes. Inpatient psychosocial interventions are provided in both specific and generic facilities, offering long-term and short-term treatment, often combined with inpatient detoxification. Detoxification treatment is primarily carried out in inpatient facilities, but it is increasingly available in outpatient settings. New target groups for treatment service providers are immigrants, pregnant women, young people, older drug users and persons with psychiatric comorbidity; special treatment programmes are available also for cocaine or cannabis users.

OST is widely available and has become the most important form of treatment in Austria, and is often provided by general practitioners. A psychiatrist or physician can prescribe substitution medication, as stipulated in the Oral Substitution Treatment of Opiate Addicts, and a medical officer must sign a long-term prescription. In 2009 the Narcotic Drugs Decree was amended to regulate changes to the conditions for take-home substitution medication, and to establish a requirement to obtain a second opinion for diagnosis and treatment options for patients under the age of 20. Furthermore, the Oral Substitution Further Training Decree adopted in 2005 and amended in 2009 stipulates that general practitioners and public health officers need to attend training in order to be qualified and authorised to supervise prescription and to deliver substitution treatment. The qualification licence is valid for three years. In addition to office-based medical doctors and specialised outpatient centres, substitution treatment is also provided by public health authorities, hospitals and prisons. In recent years, actions have been taken at the provincial level to improve the quality of OST services and integrate them with complimentary psychosocial support services.

In 2013 a total of 16 989 clients were receiving OST. Around 9 413 clients received slow-release morphine, 2 465 received methadone and 3 663 received buprenorphine-based medications (the remaining client share includes clients receiving levo-methadone). Taking account of coverage and the overlap between DOKLI and eSuchtmittel, it is estimated that around 22 000 clients had received drug-related treatment in Austria.

See the Treatment profile for Austria for additional information.  

Harm reduction responses

The reduction of drug-related harm is a focus of all areas of drug-related service provision in Austria. Most measures are oriented towards low-threshold assistance and to reducing the risk of problematic consequences of drug use. Specific methodological approaches such as peer support are now being employed in the framework of harm reduction. Outreach work is of central importance in this context. Outreach ranges from street work to hospital connection services. Within low-threshold facilities the prevention of infectious diseases is a major component of harm reduction service provision. Relevant activities in this field include the provision of information on safer use/safer sex condom distribution; syringe exchange and vaccination programmes; free testing for HIV and viral hepatitis, access to low-threshold HCV treatment services; and counselling. In terms of the general health of drug users, women’s services also focus on gynaecological healthcare and pregnancy. Syringe exchange programmes have been successfully established in most of the provinces in Austria (seven out of nine), as illustrated by the continuous increase in the number of syringes sold or exchanged, especially in the most recent years. Between 2003 and 2013 the number of syringes distributed through the programmes more than doubled from 1.7 million to 4.8 million (excluding syringes sold in pharmacies). This increase can also be attributed to continuous expansion of the low-threshold network, with new facilities being opened over the years. In 2013 needle and syringe exchange was available via 14 fixed sites at low-threshold services and outpatient drug services, 19 syringe vending machines located in five provinces and five sites serviced by outreach workers. It is estimated that an average of approximately 360 sterile syringes per year have been issued per injecting drug user in the context of syringe exchange. Other injecting equipment (e.g. microfilters) is frequently distributed along with sterile syringes; however, this distribution is not systematically recorded. Safer use and risk reduction in recreational settings are also considered important features of reducing drug-related harm. For example, the organisation Check-it! provides information and drug-checking services to users in these settings.

See the Harm reduction overview for Austria for additional information.  

Drug markets and drug-law offences

According to the Austrian Federal Ministry of the Interior, in 2013 some 28 227 drug-law offences were registered, which is the highest number of drug-law offences ever reported. The majority of drug use and possession offences were linked to cannabis (21 203 and 1 595 supply drug-law offences respectively).

Austria is not considered to be a drug-producing country, and most of the drugs seized are either destined for other European Union (EU) countries or are smuggled in for domestic use. Heroin mainly enters Austria via the Balkan route, and this route is also used for cocaine transported to Africa or Europe by sea. Cannabis is smuggled into the country from the Netherlands, Switzerland, Morocco and, on a small scale, the Czech Republic, while in recent years an increase has been noted in the domestic cultivation of cannabis, primarily for personal use or small-scale trafficking. Synthetic drugs seized in Austria are mostly produced in the Netherlands, while amphetamines come from Poland, although methamphetamine comes from the Czech Republic and Slovakia. The new psychoactive substances are mainly ordered on the internet and mailed from China.

In 2013 the number of seizures for all cannabis products, cocaine, amphetamine, methamphetamine and ecstasy increased when compared to previous years. The number of heroin seizures continued to decline, with 80 kg of substance seized, which is almost three times less than in 2012. However, it should be noted that the quantity of heroin seized in 2012 was exceptionally high compared to previous years. The seized amount of herbal cannabis almost doubled compared to 2012 (1 431.55 kg in 2013; 811.81 kg in 2012), and the quantity of cannabis plants seized was higher than in 2012 (195.79 kg in 2013; 172.94 kg in 2012), but below the level seized in 2010 and 2011 (307.5 kg in 2010; 219.4 kg in 2011), while the quantity of cannabis resin seized fell when compared to 2012 (129.66 kg in 2013; 173.75 kg in 2012). The reported amounts of seized cocaine are steadily declining over the years. In 2013 a total of 24.74 kg of cocaine was seized, which had a value almost 10 times less than that reported in 2010. The quantity of amphetamine seized in 2013 was lower than in 2012, while the quantity of methamphetamine seized more than doubled when compared to 2012 (7.57 kg in 2013; 3.23 kg in 2012). The number of ecstasy seizures slightly increased in 2013 compared to 2012, and the total amount of ecstasy seized continued to decline to levels reported in 2009, following an increase in 2011. Further analysis indicates that high-purity ecstasy prevails in the market for all ecstasy forms (pills, powder and crystalline).

Look for Drug law offences in the Statistical bulletin for additional data.  

National drug laws

The Narcotic Substance Act came into force in 1998, and continued the Austrian drug policy approach of making a clear distinction between criminals trafficking in drugs and people with drug-related health problems. The law distinguishes between these two categories using several criteria, with the quantity of drugs involved (above or below the threshold, as defined by the Ministry of Health) as the most relevant factor. Penalties may vary according to whether the drug is classed as a narcotic or psychotropic. Special provisions exist for cannabis and hallucinogenic mushrooms.

The use of drugs is not mentioned as an offence. The sentence for the possession of drugs for personal use is up to six months in prison or a fine, if the quantity of drugs is not over the defined threshold. A range of alternatives to punishment is in place, including mandatory suspension of proceedings in certain defined cases of possession and for the acquisition of small amounts of drugs for personal use. Therapy instead of imprisonment may also be offered to drug addicts who have committed a more serious crime and are willing to undergo treatment. However, if aggravating circumstances apply, such as the involvement of minors or commercial intent, the penalty is up to three years’ imprisonment.

The maximum penalties for trafficking large quantities (more than 15 times the threshold quantity) were increased in 2008, to two or three years for possession depending on the type of drug, five years for import or production, and 1–10 years to 10–20 years or life imprisonment for some crimes, depending on particular circumstances (i.e. commercial purposes, membership of a gang, previous convictions and amount of drugs involved).

To inhibit the trade in new psychoactive substances, the New Psychoactive Substances Act and New Psychoactive Substances Regulation came into force in 2012. Distribution or selling of substances listed in Annex I of the Regulation, which may be defined in groups using the generic approach, is considered a violation and may result in imprisonment of up to two years for basic offences, while the punishment may be between 1–10 years when distribution of the substance has led to serious bodily harm or death. Possession of new psychoactive substances for personal use is not punishable.

Go to the European Legal Database on Drugs (ELDD) for additional information.  

National drug strategy

Austria currently has no national (federal) drug strategy or action plan document. However, a national prevention and addiction strategy, as planned in the Government Policy Statement 2013–18, is being developed. Funded by the Federal Ministry of Health, a Delphi study was undertaken based on an expanded definition of prevention, taking into account both drug use and forms of addiction not related to substances. Following the study’s completion, the Ministry of Health has established a working group to take the strategy’s development forward.

The goals and principles of the Austrian drug policy are reflected in its legislative texts. The main objective of policy is a society as free from addiction as possible, with a central principle being to define drug dependence as a disease and consequently draw a distinction between drug dependence and trafficking. These elements can also be found in the drug and addiction strategies or concepts of the nine Austrian provinces, which have been developed between 1991 (Vorarlberg) and 2003 (Upper Austria). While Carinthia’s addiction plan was extended to 2016, several other provinces have developed new strategies. In December 2010 Lower Austria adopted its addiction plan for 2011–15 based on the four pillars of: prevention; advice and treatment; social integration; quality assurance and documentation.

In 2011 Styria launched its new addiction policy, which addresses demand and supply reduction issues and places a focus on, inter alia, harm reduction and addressing prescription medication abuse and other non-substance related forms of addiction alongside illicit drug problems. The new 2012 drug strategy for Tyrol also addresses illicit drug problems, licit drugs and other forms of addiction. While Salzburg originally adopted its drug action plan in 1999, in 2011 it finalised the evaluation of the measures in place in order to advance the drug support and treatment system. Vienna launched its new addiction and drug strategy in 2013, with an emphasis on social integration, low-threshold service provision, and new substances and forms of addiction.

Downloads

Coordination mechanism in the field of drugs

At the federal level there are two interlinked structures for coordinating drug policy. The first of these, the Federal Drug Coordination Office, is attached to the Ministry of Health and is responsible for drug policy coordination. It manages the operational coordination of federal drug policies, prepares drug-related ministerial decisions and participates in European and international drug policy forums on Austria’s behalf. Comprised of three permanent representatives from the Ministry of Health, the Ministry of the Interior and the Ministry of Justice, participants from other ministries are involved on an ad hoc basis.

The second coordination structure at the federal level is the Federal Drug Forum, which supports the Federal Drug Coordination Office and functions as a coordination and advisory body in cooperation matters with Austria’s nine provinces. It consists of members from federal ministries, drug representatives and/or addiction coordinators from all nine provinces, the Local Government Federation, the Gesundheit Oesterreich GmbH including Austria’s National Focal Point, together with other scientists and experts in the drug field.

At the provincial level there are three main mechanisms for coordinating drug policy. The Provincial Conference of Drug Coordinators facilitates inter-regional drug policy coordination among the provinces. It is tasked with establishing joint positions and statements. Provincial representatives manage the coordination of actions in the drugs field. Each province appoints a representative, referred to as addiction coordinators, addiction representatives, drug coordinators or drug representatives. Drug or Addiction Coordination Offices and Addiction Prevention Units have also been set up in all of Austria’s provinces.

Public expenditure

The available information does not allow the size and trends of drug-related public expenditures in Austria to be reported.

However, in 2013 a study on the cost of addiction estimated that the use of illicit drugs results in an annual cost totalling EUR 278 million (Kreutzer, A., 2013). This cost comprises healthcare expenditure, social expenditure and state expenditure (for police and court activities), and is estimated to amount to EUR 135 million, EUR 51 million and EUR 96 million respectively.

Drug-related research

In Austria there is a broad range of approaches to drug-related research, at both the national and the provincial level. Recent and ongoing studies mentioned in the 2014 Austrian National report include responses to the drug situation and consequences of drug use, but prevalence incidence, patterns of drug use and mechanisms of drug use were also mentioned. Drug-specific research is funded at the national level by ministries and foundations promoting research, indirectly from the budgets of universities, and also from the budgets of the provinces and within the framework of EU programmes. The results of research are disseminated in scientific journals, research reports and via dedicated websites.

See Drug-related research for more detailed information. 

Key national figures and statistics

p Eurostat provisional value.

b Break in series.

e Estimated.

1 Gross domestic product (GDP) is a measure of economic activity. It is defined as the value of all goods and services produced less the value of any goods or services used in their creation. The volume index of GDP per capita in Purchasing Power Standards (PPS) is expressed in relation to the European Union (EU-27) average set to equal 100. If the index of a country is higher than 100, this country's level of GDP per head is higher than the EU average and vice versa.

2  Expenditure on social protection contains: benefits, which consist of transfers, in cash or in kind to households and individuals to relieve them of the burden of a defined set of risks or needs.

3 Unemployment rates represent unemployed persons as a percentage of the labour force. Unemployed persons comprise persons aged 15 to 74 who were: (a) without work during the reference week; (b) currently available for work; (c) actively seeking work.

4 Situation of penal institutions on 1 September, 2012.

5 Share of persons aged 0+ with an equivalent disposable income below the at-risk-of-poverty threshold, which is set at 60 % of the national median equivalised disposable income (after social transfers).

Key figures
  Year  Austria EU (27 countries) Source
Population  2014 8 506 889 506 824 509 ep Eurostat
Population by age classes 15–24  2014 11.9 %  11.3 % bep Eurostat
25–49 35.5 % 34.7 % bep
50–64 20.0 %  19.9 % bep
GDP per capita in PPS (Purchasing Power Standards) 1  2013 128 100 Eurostat
Total expenditure on social protection (% of GDP) 2  2012 30.2 % 29.5 % p Eurostat
Unemployment rate 3  2014 5.6 % 10.2 % Eurostat
Unemployment rate of population aged under 25 years  2014 10.3 % 22.2 % Eurostat
Prison population rate (per 100 000 of national population) 4  2013 104.5  : Council of Europe, SPACE I-2013
At risk of poverty rate 5  2013 16.6 %  14.4 %  SILC

Data sheet — key statistics on the drug situation

        EU range      
  Year   Country data Min. Max. Average Rank Reporting Countries
Opioids                
Problem opioid use (rate/1 000) 2013 1 4.99 0.2 10.7   17 21
All clients entering treatment (%) 2013   52.0% 6% 93%      
New clients entering treatment (%) 2013   29.5% 2% 81%      
Purity — heroin brown (%) 2013   7.6% 6% 42%   2 24
Price per gram — heroin brown (EUR) 2013 2 EUR 60 EUR 25 EUR 158   15 22
                 
Cocaine                
Prevalence of drug use — schools (%) :   : 1% 5%      
Prevalence of drug use — young adults (%) 2008   1.2% 0% 4% 2%    
Prevalence of drug use — all adults (%) 2008   0.9% 0% 2% 1% 19 26
All clients entering treatment (%) 2013   10.2% 0% 39%      
New clients entering treatment (%) 2013   11.8% 0% 40%      
Purity (%) 2013   26.1% 20% 75%   2 27
Price per gram (EUR) 2013 2 EUR 75 EUR 47 EUR 103   17 24
                 
Amphetamines                
Prevalence of drug use — schools (%) :   : 1% 7%      
Prevalence of drug use — young adults (%) 2008   0.9% 0% 3% 1%    
Prevalence of drug use — all adults (%) 2008   0.5% 0% 1% 1% 13 25
All clients entering treatment (%) 2013   3.4% 0% 70%      
New clients entering treatment (%) 2013   4.5% 0% 22%      
Purity (%) 2013   9.5% 5% 71%   9 25
Price per gram (EUR) 2013 2 EUR 45 EUR 8 EUR 63   19 21
                 
Ecstasy                
Prevalence of drug use — schools (%) :   : 1% 4%      
Prevalence of drug use — young adults (%) 2008   1.0% 0% 3% 1%    
Prevalence of drug use — all adults (%) 2008   0.5% 0% 2% 1% 15 25
All clients entering treatment (%) 2013   0.8% 0% 2%      
New clients entering treatment (%) 2013   1.1% 0% 4%      
Purity (mg of MDMA base per unit) :   : 26 mg 144 mg      
Price per tablet (EUR) 2013 3 EUR 4 - EUR 12 EUR 3 EUR 24      
                 
Cannabis                
Prevalence of drug use — schools (%) :   : 5% 42%      
Prevalence of drug use — young adults (%) 2008   6.6% 0% 22% 12%    
Prevalence of drug use — all adults (%) 2008   3.5% 0% 11% 6% 8 27
All clients entering treatment (%) 2013   30.0% 3% 63%      
New clients entering treatment (%) 2013   50.6% 5% 80%      
Potency — herbal (%) 2013   9.6% 2% 13%   14 22
Potency — resin (%) 2013   9.8% 3% 22%   7 20
Price per gram — herbal (EUR) 2013 3 EUR 5 - EUR 12 EUR 4 EUR 25      
Price per gram — resin (EUR) 2013 3 EUR 6 - EUR 12 EUR 3 EUR 21      
                 
Prevalence of problem drug use                
Problem drug use (rate/1 000) : 1 : 2.0 10.0      
Injecting drug use (rate/1 000) :   : 0.2 9.2      
                 
Drug-related infectious diseases/deaths                
HIV infections newly diagnosed (rate/million) 2013   2.5 0.0 54.5      
HIV prevalence (%) 2012/2013   1.5% - 10.6% 0% 49%      
HCV prevalence (%) 2012/2013   31.3% - 59.9% 14% 84%      
Drug-related deaths (rate/million) 2013   16.3 1.5 84.1      
                 
Health and social responses                
Syringes distributed 2013   4 762 999 124 406 9 457 256      
Clients in substitution treatment 2013   16 989 180 172 513      
                 
Treatment demand                
All clients 2013   3 631 289 101 753      
New clients 2013   1 569 19 35 229      
All clients with known primary drug 2013   2 957 287 99 186      
New clients with known primary drug 2013   1 225 19 34 524      
                 
Drug law offences                
Number of reports of offences 2013   28 227 429 426 707      
Offences for use/possession 2013   25 348 58 397 713      

Notes

See the explanatory notes for further information on the methods and definitions.

Only the most recent data are available for each key statistic. Data before 2006 were excluded.

1 - Poly-drug use including opiates. According to other sources of data this is by far the main group of problem drug users in Austria.

2 – Data refers to the mode, not the mean.

3 - Data presented are the minimum and maximum value recorded.

Additional sources of national information

In addition to the information provided above, you might find the following resources useful sources of national data.

Page last updated: Tuesday, 07 July 2015